Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Moyer

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Molecular and Cellular Biology|September 19, 1998
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor networkR Pinkas-Kramarski, M Shelly, B C Guarino, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceV A Pollack, D M Savage, D A Baker, et al.
Molecular Pain|September 26, 2019
Rat Na<sub>V</sub>1.7 loss-of-function genetic model: Deficient nociceptive and neuropathic pain behavior with retained olfactory function and intra-epidermal nerve fibersB Grubinska, L Chen, M Alsaloum, et al.
Journal of Medicinal Chemistry|October 23, 2018
Discovery of Tarantula Venom-Derived Na<sub>V</sub>1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced PruritisBin Wu, Justin K Murray, Kristin L Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2018
1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na<sub>V</sub>1.7 inhibitionAlessandro A Boezio, Kristin Andrews, Christiane Boezio, et al.
Cancer Research|October 19, 2007
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitorJitesh P Jani, Richard S Finn, Mary Campbell, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2017
Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel Na<sub>V</sub>1.7Thomas J Kornecook, Ruoyuan Yin, Stephen Altmann, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
ACS Chemical Biology|August 12, 2017
Engineering Antibody Reactivity for Efficient Derivatization to Generate Na<sub>V</sub>1.7 Inhibitory GpTx-1 Peptide-Antibody ConjugatesKaustav Biswas, Thomas E Nixey, Justin K Murray, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Molecular and Cellular Biology|September 19, 1998
ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor networkR Pinkas-Kramarski, M Shelly, B C Guarino, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceV A Pollack, D M Savage, D A Baker, et al.
Molecular Pain|September 26, 2019
Rat Na<sub>V</sub>1.7 loss-of-function genetic model: Deficient nociceptive and neuropathic pain behavior with retained olfactory function and intra-epidermal nerve fibersB Grubinska, L Chen, M Alsaloum, et al.
Journal of Medicinal Chemistry|October 23, 2018
Discovery of Tarantula Venom-Derived Na<sub>V</sub>1.7-Inhibitory JzTx-V Peptide 5-Br-Trp24 Analogue AM-6120 with Systemic Block of Histamine-Induced PruritisBin Wu, Justin K Murray, Kristin L Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2018
1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na<sub>V</sub>1.7 inhibitionAlessandro A Boezio, Kristin Andrews, Christiane Boezio, et al.
Cancer Research|October 19, 2007
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitorJitesh P Jani, Richard S Finn, Mary Campbell, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 6, 2017
Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel Na<sub>V</sub>1.7Thomas J Kornecook, Ruoyuan Yin, Stephen Altmann, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
ACS Chemical Biology|August 12, 2017
Engineering Antibody Reactivity for Efficient Derivatization to Generate Na<sub>V</sub>1.7 Inhibitory GpTx-1 Peptide-Antibody ConjugatesKaustav Biswas, Thomas E Nixey, Justin K Murray, et al.
Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.
Pageof 18